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ABSTRACT 
 
Evaluation of Acute and Chronic Lesions 
in Percutaneous Coronary Intervention. 
(August 2012) 
Aaron Wheeler Roberts, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Fred J. Clubb Jr. 
 
 Metallic implants called stents are an important part of the treatment of coronary 
heart disease. While clinical trials are excellent indicators of outcomes, microscopic 
evaluation of the host tissue response to the implant is required to assess their safety and 
efficacy. However, the evaluation of human autopsy tissue containing metal implants 
presents unique challenges in order to obtain the best results. We used integrated 
microscopy techniques incorporating microCT and novel plastic histology techniques to 
demonstrate its effectiveness on human stented vessels obtained at autopsy.  
 A total of seven cases are demonstrated where our analysis techniques were able 
to elucidate the pathogenesis of the host response and identify the specific cause of the 
complications with the stented vessel seen clinically. These techniques are more cost 
effective and efficient than other techniques currently in use, which could enable them to 
be used as part of routine autopsy evaluation. The expansion of the pool of stented 
vessels able to be analyzed to include the often overlooked large population of autopsy 
cases could provide an enormous amount of data to guide future clinical trials and 
improve patient care. 
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1. INTRODUCTION 
 
 Since their introduction in the 1980s coronary stents have evolved into a widely 
used treatment for occlusive artery disease in the United States, with > 650,000 
implantations performed each year(1). However, the use of coronary stents has recently 
come under scrutiny as to whether they are any more effective than pharmaceutical 
intervention in chronic cases (2,3). The routine evaluation of these devices is often 
limited to clinical observations and coronary angiography because of the inherent 
drawbacks of traditional processing techniques for postmortem specimens. Clinical trials 
excel in their ability to present strong statistical data on the clinical outcomes of these 
kinds of therapies. But they fall short when describing the mechanisms of the disease 
process. It is in this regard that autopsy evaluation of tissues is “uniquely capable of 
providing information regarding the pathobiological phenomena that predispose those 
patients to good and adverse clinical outcomes”(4). 
 
Stented coronary artery tissue obtained at autopsy provides a valuable look at both the 
pathology of the vessel and the mechanical properties of the implanted stent (5). 
However, the available techniques for the histological evaluation of these tissues and 
stents are limited in both results and efficiency that may hinder their use in the regular 
evaluation for research studies. Paraffin embedding, the standard for histological 
processing, fails due to the compliance mismatch between the metal device and the 
surrounding tissue. During routine sectioning, the sample may collapse and become 
irrevocably damaged.  
 
The need to analyze autopsy specimens in the most efficient way possible comes from a 
growing need for human pathology data, especially when discussing “off-label” use of 
____________ 
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stents (6). Current animal trials for stents only evaluate the “on-label” use guidelines  
for the devices that are generally narrow and don’t represent all conditions that a stent 
may be implanted in (7,8).  
 
Choosing a methodology to evaluate a one-of-a-kind specimen, such as those obtained at 
autopsy, can be a challenge. This is especially true when analysis techniques are 
mutually exclusive or destructive to the sample. Therefore targeted and precise analysis 
techniques that incorporate several methodologies onto the same specimen become quite 
valuable to the researcher or clinician. 
 
Plastic embedding in different types of resins have shown to be effective in maintaining 
varying degrees of tissue morphology(9,10). These plastic embedding techniques are 
expensive and time-consuming when performed with traditional serial sectioning 
methods and cause a loss of specimen tissue during processing. When processing 
valuable specimens, inadvertent destruction of diagnostically important areas of the 
vessel is always a risk. Micro-CT, with a resolution of 13 micrometers, is capable of 
identifying gross flaws in stent structure and deployment. And using the reconstructed 
three-dimensional volume, occlusions, restenosis, calcific plaque formation, and other 
forms of vascular damage can be located(11). Micro-CT scanning can guide histology 
sectioning towards areas of interest to produce precise representative sections that do not 
cause collateral loss of tissue. These targeted sections can be compared to the entire 
three-dimensional volume to obtain more information about the overall topography of 
the vessel lesions and validate the microCT measurements.  
 
We hypothesize that integrated microscopy techniques will reduce turnaround time and 
tissue loss because sections can be extracted from specific areas without serially 
grinding or cutting through the entire specimen. High-resolution sections enable 
pathologists to gain more information from a single specimen and therefore learn more 
from individual specimens and reduce waste in the evaluation process. With an 
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expanded set of methodologies and protocols, tissue obtained at autopsy could be used 
more extensively to assess the efficacy of coronary stents. This will have both the 
advantages of increasing efficiency compared to traditional, time-consuming serial 
sectioning, and also allow cross validation of microCT findings with direct histological 
evidence in order to provide new data on the performance of stents from an often 
overlooked source. 
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2. LITERATURE REVIEW 
 
Use of Stents 
The demands for more robust evaluation of stents and PCI come from recent studies that 
call into question the appropriateness of PCI in treating patients with certain types of 
coronary heart disease. The most recent study of the appropriateness of PCI, done in 
2011, was a clinical outcomes evaluation of a large cohort of patients (500,154) over 
several years.  The study found that the use of stents was deemed inappropriate for 12% 
of non-acute indications, and appropriate for only 50-58% for non-acute indications(3). 
All acute case indications were deemed appropriate. These trends are difficult to explain 
when the primary labeled and FDA-approved use of stents is for stable patients with 
chronic angina and no other medical complications until one considers that more than 
60% of stent use is off-label (2). Chan and his colleagues were careful to stress the value 
of expanding the testing practices for both the pre-clinical and clinical phase of stent 
development, as well as post market surveillance of off-label use (3). 
 
Testing Stents 
A perfect example of the need of a more directed and inclusive testing paradigm is that 
of the development and use of drug eluting stents over the past two decades. Medical 
devices require only minimal testing in the United States in the pre-clinical and clinical 
phases because of the 510(k) route where the existence of a predicate device can be used 
as evidence of the effectiveness of the newly developed device. In short, stent companies 
can submit past evidence of the effectiveness of a device as evidence for a new device as 
long as there are reasonable similarities. This allowed the first generation of drug eluting 
stents, in particular: which are the combination of predicate bare metal stent designs and 
already proven anti-neoplastic drugs, to be brought to market much faster than other 
types of medicine. The FDA still required long-term surveillance of clinical trial patients 
(up to 5 years(2)) and an adequate study size to produce valid conclusions(4,12-16), but 
flaws in the study design can be seen in hindsight.  
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In a 2005 report of the incidence and predictors of thrombosis in DES, Iakovou and 
colleagues found increased incidence of in-stent thrombosis in “real world” patients 9 
months after implantation, significantly higher than what was seen in patients during 
clinical trials(17). Their explanation was that physicians had been discontinuing 
antiplatelet therapy in “real world” patients in the wake of observations of significantly 
less in-stent restenosis in those patients. Until then bare metal stents were producing 
high levels of in-stent restenosis, and anti-platelet therapy was important because a 
narrower lumen was more susceptible to occlusion. The physicians had no idea of the 
danger late thrombosis posed to DES implants, and were only trying to minimize the 
negative effects of dual antiplatelet therapies, which are not always well tolerated in 
some patients. Patients enrolled in the original clinical trials were all required to 
continue dual anti-platelet therapy for the course of the trial(17). 
 
Human and Animal Trials 
Following the growing concern over late in-stent thrombosis, animal trials were revisited 
in order to uncover an explanation. In 2007 Nakazawa’s group suggested why the late 
effects of DES implants were overlooked in animal trials. They showed that while pig 
and rabbit models were adequate for mechanical testing of coronary stents, the rates of 
re-endothelialization are not quite as close to those seen in humans, who take much 
longer to re-endothelialize. This discrepancy was such that the pre-clinical testing 
window of 90-180 days showed successful, albeit delayed, endothelialization of the 
lumen of the stented vessel in porcine models. However when tested in humans the 
delayed healing process can take almost a year or more to reproduce the same 
results(18). So when the same time points that were used to test successful 
endothelialization in animals were applied to recommendations for the discontinuation 
of anti-platelet therapy in human patients, DES use led to complications in “real world” 
use. Nakazawa et al. claimed that if the results of animal trials had been interpreted 
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correctly and properly scaled to human healing time points, complications in clinical use 
could have been predicted. 
 
Our understanding of the pathology of stented lesions is constantly advancing but is 
based on a key idea: the implantation of a device in the artery will elicit a response from 
the body. It is the type and cause of the response that is steadily becoming better 
understood. The vessel response to injury from an angioplasty balloon was described in 
1987, when it was observed that endothelial disruption would lead to thrombosis in the 
injured artery(19). Later, in 1992, another group described their findings in a porcine 
model at 4 weeks after implantation that the rate of restenosis was proportional to the 
amount of medial injury from overexpansion of the vessel wall(20). An important 
distinction must be made between observations in porcine arteries and human arteries; 
because they do behave differently than human arteries. Porcine arteries endothelialize 
and recover from injury much faster(21), but more importantly they are not often 
diseased when used for testing of stent implants(22). And those conclusions drawn from 
porcine studies should be compared to equally rigorous studies in diseased human 
arteries containing plaques. In 1999 Farb et al. described the differences in the pathology 
of human stented lesions, compared to porcine models, and concluded that while most 
injury in human implants is associated with the plaque, porcine injury often involves the 
media directly(23). Furthermore the rapid re-endothelialiation of the pig sequesters fibrin 
around the struts of the stent, limiting their exposure to the lumen and possibly limiting 
thrombosis in pigs(22).  
 
Another study in 2006 by Joner and colleagues again confirmed that human arteries 
endothelialize slower than porcine arteries(21). In addition, they confirmed that first 
generation drug eluting stents in humans show delayed healing and hypothesized that the 
delayed healing process places vulnerable lipid plaques at risk of rupture and exposure 
of thrombogenic material to the lumen(21). That same year another group showed that 
prolonged damage to the endothelium or other limits to healing leads to increased 
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frequency of thrombus formation on its own, even when patients were on dual anti-
platelet therapy(15). To try and uncover the mechanism of thrombus formation, a study 
was done in 2007 using atherectomy to identify the type of material in the vessel wall 
that was initiating a thrombogenic response. They found an incomplete neointima over 
two years after implantation (24,25). Because the endothelium of the vessel wall 
remained unhealed, the inflammatory and thrombogenic pathways were at risk of being 
triggered even at long-term time points (26). Because of this van Beusekom and 
colleagues advocated extending dual antiplatelet therapy for patients already implanted 
with DES, and the deployment of long term studies that correlate both histology and 
imaging to better understand the mechanisms behind late thrombosis. 
 
Next Generation Drug-Eluting Stents 
The second and third generation of drug eluting stents, currently being developed and 
tested, were inspired by several studies that demonstrated a link between restenosis, neo-
intima plaque formation, and the inflammatory response(5,27,28).  In 2002 Farb’s group 
commented on how, even though the first generation of DES using anti neoplastic agents 
to suppress smooth muscle cell proliferation were successful, the addition of anti-
inflammatory drugs might help further temper the reaction(5). A new model of DES 
utilizing pimecrolimus in porcine models has shown promising results for decreasing 
restenosis and late thrombosis (29,30). However long term human trials will be the 
deciding factor because both the FDA and the scientific community have taken note of 
the lessons learned from the first generation of DES(13). With over 6 million DES 
currently implanted in human patients, the need for a direct histopathological evaluation 
process that can elucidate mechanisms of disease is apparent.(13) 
 
Direct observation of tissue associated with the healing process of stented arteries is 
crucial to settle the current debate over the nuances of the exact mechanisms of disease 
and healing. Whereas past studies before 2012 have suggested incomplete 
endothelialization as the culprit for late in-stent thrombosis, new research is revealing 
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that it may be more complicated. Recent findings using angioscopic imaging have shown 
that the degree of neointimal coverage is not related to the prevalence of in-stent 
thrombosis. Instead, the host reaction is more directly related to the health and type of 
the endothelium, the type of polymer coating, drug, dose, and other stent 
characteristics(31). The long-term onset and low frequency of thrombosis also presents a 
challenge to researchers trying to reliably reproduce lesions for study, especially as 
current recommendations for long term antiplatelet therapy garnered from first 
generation DES outcomes would put patients at too much risk to ethically test the effects 
of dual anti-platelet therapy in clinical trials, a limitation that may confound the results 
of clinical analyses(32).  
 
Regardless of the concerns for the safety and the future analysis of DES, the technology 
is a promising and inspired step forward in improving medical implants. Because the 
high risk of restenosis in BMS outweighs the risk of late thrombosis in DES, there is no 
difference in mortality from BMS compared to first generation DES as long as patients 
continue to take long term anti-platelet therapy(33). Of course, the need to find a device 
that avoids the need for anti-platelet therapy in patients that may not tolerate the 
treatment due to secondary factors still exists. DES are also the indicated treatment for 
restenosis of BMS based on clinical outcomes. However all the different factors 
involved for re-implantation of another stent are not well studied at the microscopic 
level, and there is limited data regarding the optimal use of DES in such cases(12). 
Furthermore, DES still require direct pathology observation along with microscopic 
evaluation and other methodologies in order to confirm the performance of the stent at 
all levels of testing moving forward(12,34). 
 
Micro Computed Tomography 
MicroCT scanning is a robust technology for the evaluation of materials and tissues in 
three dimensions. The technology using a series of x-ray micrographs that are then 
reconstructed into a volume by a computer(35). MicroCT was first used for bone and 
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bone implants, and has been proven to provide good correlation to histology(36). The 
feasibility of microCT scanning when applied to autopsy specimens of coronary artery 
wall lesions has been described by Langheinrich et. al. when they analyzed vulnerable 
plaques and the nature of underlying lesions in acute coronary events(37). They stated in 
their rationale for the use of microCT that histology on its own is limited as an analysis 
tool. Their concerns included the expensive and time consuming nature of serial 
sectioning, the destruction of the tissue that causes it to be excluded from other analysis 
methods, and the lack of three-dimensional data that precludes longitudinal 
measurements. The idea of an integrated approach to medical device evaluation that 
incorporates CT imaging and histology was first described in 2008(38). Jason Foerst 
demonstrated stent analysis using microCT in 2010 when his group scanned and 
reconstructed an entire stented vessel from a patient that had received two stents 5 
months before death. In their findings they noted the ability of the microCT 
methodology to reveal fractures in the stent struts as well as the location and 
morphology of calcified plaques in the vessel wall and along the stent. Their analysis 
was limited to an evaluation of the performance of the device by observing the fracture 
patterns(11).  
 
Histology 
Histological processing of metal stent implants has come a long way in the last two 
decades. Originally, struts had to be manually removed from the tissue following 
fixation but before embedding(39). This process was necessary because tissues are 
usually embedded in paraffin wax, which does not tolerate the presence of metal in the 
block. A method of using methyl-methacrylate (MMA) plastic resins was introduced in 
1996 that demonstrated the implant could be left in the tissue during processing and then 
cut on a motor driven rotary microtome(40). The problem with these plastic sections is 
that they are difficult to stain due in a large part to their hydrophobic nature. Hydrophilic 
stains are unable to penetrate the hardened plastic matrix, and therefore substitute stains 
using small molecular weight molecules and non-aqueous solvents were developed(41). 
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To improve cellular detail and increase the number of available stains for plastic 
embedded tissues: deplastination techniques were developed. The caveat is that only 
certain types of plastics could be removed from the section, and they are usually the 
most volatile, and dangerous to handle(9). In 2006 Peter Rippstein et. al. published a 
review of the available plastic sectioning techniques to determine which produced the 
best, most reliable, results(42). In their conclusion they noted that using a microtome 
produced sections with the most consistent thicknesses. However, the high potential for 
blade damage due to the dense metal struts could cause unwanted artifact. The 
alternative is to use a sawing and grinding method (SG), also referred to as 
microgrinding, which they stated “consistently produces intact specimen sections 
without displacement of the struts or scoring of the tissue.” The drawback is the plastic 
in SG sections cannot be removed safety because of microscopic scoring lines from the 
grinding process that fray and produce artifact. Therefore the staining and cell detail 
seen in SG sections is usually of lower quality. Rippstein’s group did, however, discover 
that using heat during the staining process improves the contrast of the final result(42). 
One year after their review, a new type of plastic embedding media was invented, called 
Technovit 7200. This resin is a variant of methyl methacrylate, called isobornyl 
methacrylate, which is much harder and shrinks less during processing so the 
architecture of the tissue is much better maintained during processing. Furthermore the 
resin is a light hardening monomer instead of a catalyzed polymer like MMA, and is 
much less volatile and dangerous to use. However it is significantly more hydrophobic 
than MMA and cannot be removed from the section so it is more difficult to stain(43).  
Other methods of processing metal stent implants that avoid using plastic have been 
suggested, such as using electrochemical processes to dissolve the stent in a salt acid 
bath under DC current (44). 
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3. METHODS 
 
Human Autopsy Specimens 
Stented vessels obtained from human patients at autopsy showing signs of severe 
coronary artery stenosis, calcific plaque formation or coronary artery disease were 
provided from the Texas Heart Institute (Houston, TX, USA). There were 12 cases in 
total, 7 of which are presented in this paper because they showed results relevant to the 
demands of clinical evaluation of stents (Table 1). These cases were analyzed as part of 
a clinical autopsy evaluation service provided by the Cardiovascular Pathology 
Laboratory at Texas A&M University. Relevant clinical information was collected 
where available and patient identities were anonymized. The patients were implanted 
with metallic stents at varying time points for different durations but all showed 
complications arising from the stent implantation or the areas related to the implanted 
stents. The specimens were fixed in 10% neutral buffered formalin at the time of 
autopsy. All specimens were evaluated according to standard operating procedures 
developed by the Cardiovascular Pathology Laboratory for the analysis of metal 
implants. Methodologies used include microCT, with contrast material in the lumen if 
necessary, and targeted microground histology on areas of interest in the specimen. 
Specimens were grouped by type of stent and implant duration.  
 
High Resolution Digital Photography 
A high-resolution digital single lens reflex camera (Canon Mark 3, Canon Inc., Lake 
Success NY) was utilized to photograph each specimen from multiple perspectives. 
Gross features were noted for analysis and the photographs will serve as a record of the 
gross orientation and appearance of the specimens. 
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Table 1: Summary of Evaluated Cases 
Case 
# 
Case Type Time Stent Type Clinical History Microscopic Findings 
1 
Acute 
N/A Liberte Taxus 
Paciltaxel-
Eluting 
Stent implanted in the RCA for acute MI. 
Evidence of eroded plaque with thrombus 
downstream. No reflow phenomenon. 
Eroded/ruptured plaque in the RCA. Unable to 
tell if it was associated with the procedure. 
2 
N/A Medtronik 
Integrity Bare-
Metal 
Stent in proximal left main. Presented with 
acute coronary syndrome 
Severe mineralized plaques in a branch artery 
expanded on implantation and lead to rupture of 
the vessel wall with concurrent stent fracture. 
3 
1 wk Boston Scientific 
Liberte BMS 
Stent in LCX. Presented with multiple 
healed sub-acute to acute MI, Patient did 
not take Plavix due to cost issues. 
Focal soft plaque rupture and erosion. Evidence 
of thrombogenesis consistent with clinical signs. 
4 
N/A J&J Cordis 
Cypher 
Sirolimus-Eluting 
Stent placement on admission to L. 
circumflex obtuse. 10% stenosis post-
deployment. Peri-procedural MI. 
Stent deployed against a mural thrombus with a 
thin fibrous cap. Dissections of the cap and 
rupture of soft plaque. 
5 
Chronic 
2yr Abbot Multilink 
Vision Bare-
Metal 
76 y/o female. Presented with acute 
coronary syndrome and died after CBG 
Focal calcification produced an area of 
contralateral overexpansion and IEL rupture 
6 
6yr J&J Cordis 
Cypher 
Sirolimus-Eluting 
Male, unknown age. DES implant in 
LCCA in 2004. Presented with severe 
CAD. 
Interrupted healing of the endothelium and peri-
strut region. Exposed struts in the lumen 
7 
9yr + 
2yr 
Multiple 
DES/BMS 
History of CAD. >10 stents in the RCA Neo-intima proliferation in the region of media 
rupture. In-stent atherosclerosis with 
mineralization. Degeneration of the media and 
IEL in the distal RCA. 
A total of 7 cases were evaluated using integrated microscopy techniques. The clinical history and indications as well as relevant findings for 
each case are summarized. 
12 
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MicroCT Analysis 
Samples were scanned using a HAWK-160XI (Nikon, Chiyoda-ku, Tokyo) microCT 
system. The system uses a cone-beam X-ray detector and source configuration for image 
acquisition with a tungsten target for generating X-rays up to 160kV. Approximately 
1000 projections were completed for each scan with an average of two scans performed 
on each vessel. Samples that remained patent were injected with 50% (wt/vol) barium 
sulfate (Electron Microscopy Sciences) solution for improved lumen contrast. The 
scanning process was carried out with Inspect-X software (Nikon) and volumes were 
reconstructed with CT-Pro (Nikon). MicroCT data was analyzed in VGStudioMAX 
(Volume Graphics GmbH, Heidelberg, Germany).  The three-dimensional scan data was 
analyzed first for stent fractures and overall structural integrity. Samples still containing 
calcium deposits were then analyzed for calcium content by adjusting the display 
window to show mineralized areas. When possible, areas of high restenosis were 
visualized by highlighting the vessel tissue or by injecting a barium sulfate contrast 
agent. Soft tissue contrast was minimal due to the energy levels being above 100kV and 
the presence of beam hardening artifact from the metal stents. Traditional two 
dimensional x-ray micrographs were taken using the same equipment in both en face and 
lateral orientations. 
 
Histology 
Samples were dehydrated through graded alcohols and then infiltrated in Technovit 7200 
(Heraeus Kulzer, Wehrheim, Germany) methacrylate resin according to the 
manufacturer’s instructions. Specimens were polymerized overnight in Technovit 7200 
in the Exakt Light Polymerization Unit (Exakt, Norderstedt, Germany). 
 
The Exakt System (Exakt, Norderstedt, Germany) microgrinder and high-precision 
diamond band saw were used for sectioning tissue samples(45). Three-dimensional 
reference points taken from MicroCT slice data and measurements taken from high 
resolution radiographs were used to cut a parallel face into the excess plastic mass 
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surrounding the specimen that aligned with the desired section. This end of the block 
was then affixed to a plastic mounting jig using Technovit 4000 adhesive (Heraeus 
Kulzer, Wehrheim, Germany). Next the diamond saw was used to split the block through 
the targeted area of interest, creating two opposing block faces within the desired region. 
The piece of the plastic block that was not attached to the jig was mounted on its own 
plastic mounting jig and faced in the same manner. This technique provides two block 
faces in the area of interest, on which a final polished thin plastic slide could be attached 
with cyanoacrylate glue (Technovit 7210, Heraeus Kulzer, Wehrheim, Germany). The 
final thin plastic slide was then cut from the block using the diamond saw 300 microns 
away from the slide. The resulting thin section was ground to a target thickness of 50 
microns using progressively finer sandpaper on the microgrinder and then polished using 
silicon dioxide 4000 grit paper and stained. 
 
Slides are stained as follows: (1) Etch slides for 2 minutes in 2% formic acid solution 
(vol/vol) (2) 5 minutes in 50% EtOH (vol/vol) (3) On a hot plate set to 55o C, place a 
bead of Gill’s #3 Hematoxylin (Electron Microscopy Sciences) over the specimen and 
allow to stain for 35 minutes (4) Rinse in distilled water and stain in a 50%/50% mixture 
of Eosin Y (Electron Microscopy Sciences) and Phyloxine B (Electron Microscopy 
Sciences) (vol/vol) (5) Rinse in distilled water and clear in 50% EtOH (vol/vol) with 2-3 
drops of Acetic Acid (Electron Microscopy Sciences). The slides should be left 
uncoverslipped and examined microscopically under a small amount of immersion oil. 
 
Digital Slide Imaging 
All digital slide images were taken using an Aperio digital slide scanner (Aperio, Vista, 
CA, USA). This scanner is capable of images at 83x resolution that can be viewed at any 
magnification. Furthermore, built-in analysis and measurement tools enable easy 
quantification and description of results. 
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4. RESULTS 
Case 1: Ruptured Soft Plaque 
This case involves an acute implant in a 68 year-old female in the proximal right 
coronary artery. According to records, the patient presented with acute myocardial 
infarction with 100% stenosis of the RCA. Following stenting there was no measured 
reflow in the RCA. The patient died moments after catheterization. Present in the RCA 
was a stent identified by CT scanning as a Boston Scientific Taxus paclitaxel eluting 
stent. Analysis of the stent by X-ray and CT shows crushing and distortion of the stent 
body and damage to the ends of the stent: this finding is most likely iatrogenic (Figure 
1A). Due to the collapsed nature of the vessel no contrast material was injected into the 
lumen. The vessel was decalcified prior to accessioning. 
 
To evaluate the aftermath of this clinical intervention serial sections were taken of the 
entire vessel to attempt to locate the culprit lesion. A total of 10 sections were produced 
and examined microscopically for signs of rupture, thrombus formation, or hemorrhage.  
 
Histology sections in the proximal and distal regions show multiple concentric 
complicated to fibrolipid plaques forming layered “piggyback” lesions that, prior to 
stenting, produced an approximately 50% lumen stenosis involving 90% of the 
circumference of the internal elastic lamina. Contralateral to the largest vulnerable 
plaque is a smaller, mildly calcified fibrolipid plaque with a thicker fibrous cap and a 
smaller lipid core. All lipid plaques in the wall of the vessel show hemosiderin-laden 
macrophages and erythrocytosis, indicative of older plaques. Post-stenting, the vessel 
lumen within the stent is nearly 100% patent. The site of rupture of the vulnerable 
plaque was located contralateral to the calcified lesion in the middle portion of the stent 
(Figure 1B). Deployment of the stent struts were not circumferential and were unevenly 
distributed. Several struts were embedded in the ruptured athermanous material 
penetrating into the lumen (Figure 1B, Green Arrows). The loose nature of the  
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Figure 1: Vulnerable Plaque Rupture. Green arrows indicate the ruptured soft plaque core; blue 
arrows indicate evidence of acute hemorrhage into the plaque. 300 micron scale bar. 
 
 
 
surrounding material led to the struts being lost during the cutting process, but the void 
where they were is still visible. Signs of acute hemorrhage were observed in this region 
as well, with evidence of acute bleeding between the media and adventitia layers in this 
and other sections distal to the rupture site (Figure 1B, Blue arrow). A nidus of ruptured 
plaque material can be seen occupying roughly 20% of the lumen, this material is not 
covered with endothelium. There are acute granulomatous infiltrates of neutrophils and 
some macrophages present in the ruptured material and in the vessel wall near the site of 
rupture. Downstream of the rupture site accumulations of platelets, enmeshed 
erythrocytes, and fibrin are observed along the vessel wall adhered to struts in the lumen 
and occupying the lumen itself. Stent struts observed microscopically show no signs of 
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endothelialization, consistent with an acute implantation. There were no signs of medial 
disruption. 
 
Case 2: Acute Dissection 
This case is an acute implant in a 60 year-old male in the proximal left main artery. 
According to records, the patient presented with acute coronary syndrome with 100% 
stenosis of multiple arteries in the left main and its branches. Following stenting there 
was a reported 10% stenosis, however runoff was still poor. Regardless of stenting the 
patient had already developed significant myocardial infarction that led to his death.  
 
Present in the proximal left main was a stent identified by CT scanning as a Medtronic 
Integrity bare metal stent. Analysis of the stent by X-ray and CT shows crushing and 
distortion of the stent body and with multiple fractures and incomplete deployment 
hindered by the presence of a severely calcified vessel wall (Figure 2A). Furthermore, 
CT imaging shows the proximal end of the device deployed over a branch artery that is 
also heavily calcified. Of note, a broken strut can be seen protruding into the wall of the 
vessel between two calcified lesions on the proximal end of the vessel (Figure 2A, green 
arrows). Due to the collapsed nature of the vessel injection of contrast material into the 
lumen was unsuccessful. Remnants of the contrast material are rendered as gray in the 
microCT reconstruction, and fragments can be seen in the lumen of the vessel on 
histology (Figure 2). The vessel was not decalcified prior to accessioning; calcium is 
rendered as blue in the image. 
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Figure 2: Calcified Plaque Dissection. (A) the strut protruding into the vessel wall (green arrow), 
mineralized plaque is shown in blue. (B) Shows the dissection site and protruding strut (green 
arrow). (C) shows a magnified view of the dissection site. (D) Shows the edematous hemorrhage with 
extravagation of erythrocytes. 300 micron scale bars. 
 
 
 
In such a heavily calcified lesion the most probable location for stent deployment 
complications would be regions where the soft tissue could be damaged in between the 
calcified plaques. Targeted histology sections were directed toward a broken strut 
protruding into the lumen, as well as several millimeters proximal and distal to the site. 
A total of 10 sections were produced proximal and distal to the protrusion site and 
examined microscopically for signs of rupture, thrombus formation, or hemorrhage.  
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Histology sections at the rupture site show a multiple, concentric complicated plaques 
with severe multifocal to confluent areas of mineralization that, prior to stenting, 
produced an approximately 60% lumen stenosis involving 60% of the circumference of 
the internal elastic lamina. Similar calcified plaques can be seen in the branch arteries 
immediately adjacent to the stented artery. MicroCT confirms that the mineralized 
plaque is continuous with the mineralized plaque in the proximal left main. Contralateral 
to the mineralized plaque, the media of the vessel wall is very thin with the struts of the 
stent deforming the media and coming very close to the adventitial collagen. Several 
struts on the contralateral side were away from the vessel wall in the lumen, most likely 
due to handling artifact. The protruding stent can be seen dissecting the vessel wall 
through the media (Figure 2C green arrow). Surrounding the dissection site are signs of 
acute hemorrhage and edematous bleeding between the media and adventitia (Figure 
2D). There are signs of mild acute granulomatous infiltrates of neutrophils and some 
macrophages present in the hemorrhaged material and in the vessel wall near the site of 
rupture. Sections taken proximal and distal to the rupture site confirm the length of the 
dissection to be several millimeters long, corresponding to the small gap between the 
mineralized plaques of the proximal left main and its branch artery; both of which show 
signs of deflection and separation on microCT. Stent struts observed microscopically 
show no signs of endothelialization, consistent with an acute implantation. There was no 
evidence of thrombus formation either local or remote. 
 
Case 3: Vulnerable Plaque Erosion and Thrombosis 
This case involves an acute implant in a 62 year-old male in the proximal left circumflex 
coronary artery. According to records, the patient had a stent implanted 1 week prior to 
admission for acute myocardial infarction. At autopsy there were multiple healed, acute, 
and sub-acute infarcts found in the heart muscle downstream of the implant site. It 
should be noted that the patient did not take Plavix due to cost issues. 
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Present in the proximal left circumflex obtuse artery was a stent identified by CT 
scanning as a Boston Scientific Liberte drug eluting stent. Analysis of the stent by X-ray 
and CT show an intact device with moderate distortion of the proximal region, most 
likely due to handling and extraction artifact (Figure 3A). The vessel contained many 
focal to confluent mineralized plaques around the middle region of the stent, shown in 
dark gray. Because of the presence of post-mortem clotted blood the lumen could not be 
injected with contrast material. The vessel was not decalcified prior to accessioning. 
 
Targeted histology sections were taken from the most proximal region of the stent just 
before the damaged region. (Figure 3A, red line). Additional sections were taken several 
millimeters distal to the targeted site. A total of 9 sections were produced and examined 
microscopically for signs of rupture, thrombus formation, or hemorrhage.  
 
Histology sections at the target site show a large, concentric soft atheromatous plaque 
with a lipid and cholesterol core and two large areas of focal to confluent mineralization 
located on opposite sides of the vessel that, prior to stenting, produced an approximately 
85% lumen stenosis involving 100% of the circumference of the internal elastic lamina. 
The lumen of the vessel at this level is dominated by a “chicken fat and currant jelly” 
post-mortem blood clot that continues downstream to the distal end of the vessel (Figure 
3B). The athermanous plaque shows signs of erosion and minimal endothelial coverage 
at the aneurismal extension of the plaque into the lumen (Figure 3 B-C, green arrows). 
Peristrut fibrin deposition is present around all of the stent struts, along with apparent 
lack of endothelialization between or upon the stent struts. 
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Figure 3: Effects of No Antiplatelet Therapy. (A, B, C) show the site of erosion of the soft plaque, 
300 micron scale bar. (D, E, F) show the location of focal rupture with infiltration of erythrocytes 
and fibrin into the center of the plaque, 300 micron scale bar. 
 
 
 
There are signs of mild to moderate granulomatous infiltrate present in the plaque as 
well as the fibrous accumulations along the vessel wall. Sections taken distal to the 
target site show extensions of the fibrous accumulations along the vessel wall and 
around the stent struts (Figure 3 D-F, blue arrows). Erythrocytes in the core of the 
plaque, with extensive fibrin accumulation can be seen in sections of the middle portion 
of the stent with fibrin lipid material exposed to the lumen (Figure 3 D-F, blue arrows). 
Port mortem blood clotting also obscures the vessel lumen in the proximal sections. 
There appears to be strong evidence of the formation of a thrombogenic nidus secondary 
to plaque rupture proximal to section shown in figure 3; however, because of handling 
damage sections could not be taken of this area. 
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Case 4: Mural Thrombus 
This case is an acute implant in a 63 year-old male in the proximal left circumflex obtuse 
artery. According to records, the patient presented with acute coronary syndrome prior to 
stenting. Following stenting there was a reported <10% stenosis, however the patient 
died moments later of a peri-procedural acute myocardial infarction. 
 
Present in the proximal left circumflex obtuse artery was a stent identified by microCT 
scanning as a Cordis (Johnson and Johnson) sirolimus eluting stent. Analysis of the stent 
by X-ray and CT shows an intact device with no evidence of disruption or fracture  
(Figure 4A). The stent was slightly bent in the region of the third-most proximal ring, an 
area that also contains a small, mineralized plaque. In addition microCT imaging shows 
the proximal end of the device deployed over a branch artery. The lumen was injected 
with contrast material, shown in gray on the reconstruction. The vessel was not 
decalcified prior to accessioning; calcium is rendered as dark gray in the image. 
 
Targeted histology sections were taken from the bent region of the stent near the 
calcified plaque (Figure 4A, red line). Additional sections were taken several millimeters 
proximal and distal to the targeted site. A total of 3 sections were produced and 
examined microscopically for signs of rupture, thrombus formation, or hemorrhage.  
 
Histology sections at the target site show a large, concentric fibrous plaque with a lipid 
and cholesterol core and small multifocal to confluent areas of mineralization that, prior 
to stenting, produced an approximately 70% lumen stenosis involving 100% of the 
circumference of the internal elastic lamina. Sections proximal to the target site show an 
old, dense, organized mural thrombus with a fibrous cap roughly 100 micrometers thick 
on the luminal side. This feature continues along the length of the stented vessel and can 
be seen in the target and distal sections as well. 
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Figure 4: Mural Thrombus Dissection. (A) Red line representing the plane of sectioning distal to a 
branch artery near a bend in the stent. (B) Showing the mural thrombus (green arrows) with 
dissected fibrous cap and plaque rupture site (blue arrows). (C) Showing a closer view of the 
exposed mural thrombus (green arrows). (D) Showing a closer view of the ruptured plaque (blue 
arrows) adjacent to focal mineralization. 300 micron scale bars. 
 
 
 
In the target section, however, the fibrous cap is pulled away from the wall and the 
thrombus is exposed to the lumen (Figure 4B, 4C green arrows). Just lateral to the mural 
thrombus is the mineralized lipid and cholesterol core of the fibrous plaque. On one end 
of the plaque a stent strut can be seen intruding into the core of the plaque, exposing the 
lipid and collagen substrate to the lumen of the vessel (Figure 4D, 4B blue arrows). 
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There are signs of mild acute granulomatous infiltrates of neutrophils present in the 
vessel wall near the site of rupture. Sections taken distal to the rupture site show similar 
infiltrates, as well as platelet and fibrin accumulation around the stent struts and along 
the vessel wall. MicroCT confirms the formation of in-stent fibrous accumulations distal 
to the target section with a gradual tapering of the luminal area starting just distal to the 
bend in the stent. Stent struts observed microscopically show no signs of 
endothelialization, consistent with an acute implantation; however, many of the struts are 
covered with accumulations of fibrin and enmeshed erythrocytes. There appears to be 
strong evidence of the formation of a thrombogenic nidus at the target section location 
that may have been sending emboli downstream, consistent with clinical observations. 
 
Case 5: Overexpansion Contralateral to a Hard Plaque 
In this case a 76 year-old female presented with acute coronary syndrome and died after 
coronary artery bypass grafting (CABG). Present in the right coronary artery were BMS. 
The most proximal was collected, decalcified, and stored in archive at the Texas Heart 
Institute (THI) before submission to our lab for processing. This stent, according to 
record, was implanted 2 years prior to the demise of the patient. Analysis of the stent by 
X-ray and CT in situ revealed a focal over-expansion of the stent struts (Figure 5, green 
arrows) contralateral to a series of struts that remained under-deployed.  
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Figure 5: Over-Expanded Strut Contralateral to a Calcified Plaque. X-ray micrograph and 
MicroCT reconstructions of the implant. Green arrows indicate the over-expanded strut. Red line 
indicates the target section for histology. MicroCT cross section is at the level of the red line. 
 
 
 
Unfortunately, this vessel was decalcified prior to receipt at our lab; therefore the extent 
of the presumed calcification in the region of the deformation could not be characterized 
by radiological imaging alone. To observe the vessel morphology at the site of the 
deformed strut, a section was taken that intersects where the strut protrudes into the 
vessel wall and the presumed calcific lesion on the opposite side (Figure 5, red line). 
When this cross section is isolated in the CT volume the uneven distribution of struts 
suggests possible incomplete expansion at the time of implantation (Figure 5).  
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Figure 6: Internal Elastic Lamina Rupture Site. (A) Subgross view of the entire section. (B) Site of 
medial disruption by over-expansion. (C) Close-up view of the peristrut region at the rupture site. 
300 micron scale bars. 
 
 
 
Histology sections of this area show an eccentric plaque that, prior to stenting, produced 
an approximately 50% lumen stenosis involving 25% of the circumference of the 
internal elastic lamina (Figure 6). This is primarily a fibrolipid plaque with areas of focal 
to confluent mineralization at the center of the substrate. This plaque formed a dense, 
unyielding, barrier to the expansion of the struts of the stent within its proximity that 
resisted the expansion force of the angioplasty balloon. The force was redirected towards 
the path of least resistance (toward the contralateral side) and led to the overexpansion of 
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the struts in that area. Microscopic evidence supports this theory due to the observed 
uneven distribution of the stent struts opposite the plaque, and the presence of stent struts 
outside the internal elastic lamina that are resting in the media of the vessel (Figure 6b). 
Upon closer inspection of a different region of the stented lesion, distal to the first 
section in the second-most distal ring of struts, we found a fragment of the internal 
elastic lamina resting within the media of the vessel (Figure 7A, green arrow). 
 
To confirm the extent of the internal elastic lamina rupture, serial sections were taken 
along the length of the stented lesion. All sections contained dissected portions of the 
internal elastic lamina and suggested that the observed damage is a longitudinal tear of 
the internal elastic lamina along the length of most of the stent. This acute damage 
invoked a healing and immune response to both the disruption of the elastic lamina and 
the presence of the foreign body. The effects of which can be seen most easily by the in-
stent restenosis present along the length of the vessel that occupies, on average, 40% of 
the lumen area (Figures 6,7). The cellular composition of the areas of restenosis, 
however, is reminiscent of a healthy injury response. The endothelial cell layer is smooth 
and continuous, and there is no evidence of thrombus or thrombogenic areas in contact 
with the lumen. The substrate surrounding the stent struts and within the smooth muscle 
tissue contains a neovascular blood supply that is largely clear of debris, and only a few 
struts showed evidence of peristrut associated material (Figure 6B, 6B, green arrows). 
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Figure 7: Distal Rupture Site. (A) Subgross view of the entire section. (B) Ruptured internal elastic 
lamina (green arrow). (C) Peristrut amorphous material caused by trapping of erythrocytes and 
fibrin by neointimal proliferation (green arrows). 300 micron scale bars. 
 
 
 
Some regions of the vessel had minor areas of enmeshed erythrocytes and fibrin, 
however there was no evidence of a lasting inflammatory response. The duration of this 
implant was 2 years, so the scarcity of multinucleated giant cells, neutrophils, and 
lymphocytes is expected given the time since the original insult. Restenosis occupying 
40% of the lumen of a blood vessel would not have generated clinical signs in the 
patient. 
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Case 6: Long-Term Drug Eluting Stent 
This chronic case involves a long-term drug eluding implant in a male of unknown age 
for duration of 6 years prior to receiving a heart transplant in August 2010. Present in the 
left circumflex coronary artery (LCX) was a stent identified by CT scanning as a 
Johnson and Johnson Cordis sirolimus eluting stent. Analysis of the stent by X-ray and 
CT revealed fragmentation of the stent at a branch artery near the proximal end of the 
vessel and in the middle of the main body of the stent (Figure 8, green arrows). Contrast 
material injected into the lumen revealed no major disruptions or plaques along the 
length of the vessel. 
 
Each ring of struts was sectioned to observe the host tissue response to the drug infused 
polymer coating. A total of 9 sections were produced, 2 of which intersected with the 
fragmented portions of the stent, and examined microscopically for signs of delayed 
healing, endothelial disruption, or medial rupture 
 
Histology sections in the proximal area show an eccentric fibrolipid atherosclerotic 
plaque with cholesterol clefts and a lipid core that, prior to stenting, produced an 
approximately 60% lumen stenosis involving 40% of the circumference of the internal 
elastic lamina (Figure 9). Post-stenting, the vessel lumen within the stent is nearly 100% 
patent with minimal in-stent restenosis. Contralateral to the plaque in this section, and in 
the other sections, is evidence of rupture of the internal elastic lamina due to the 
expansion of the stent, along with medial disruption and degeneration. 
 
The media on the contralateral side is almost completely degenerated leaving only a 
small amount of space between the implant and the adventitia (Figure 9b).  In the distal 
portion of the stent, just distal to the strut fracture, the fibrolipid plaque becomes more 
calcified, but still retains its prominently visible lipid and cholesterol core. 
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Figure 8: Proximal Drug-Eluting Stent. The proximal region of the DES is deployed over a branch 
artery. At this level the struts show complete coverage, except for the strut over the lumen of the 
branch artery. (B, C) show a completely covered strut with dense fibrous cap. 300 micron scale bar. 
 
 
 
Contralateral to the plaque there is still evidence of medial disruption; however at this 
level there is an immature early resolving thrombus with mixomatous material covering 
two of the stent struts (Figure 9). Accompanying this thrombus is a moderate to severe 
cellular response over two of the struts, and a limited cellular reaction over the other four 
struts adjacent to the plaque. The nidus of the thrombus was located approximately 
2.5mm proximal to this section and seems to be involved with a portion of disrupted 
endothelium near the fractured strut. 
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Figure 9: Distal Drug Eluting Stent. The distal region of the DES show several unhealed struts still 
in contact with the vessel lumen. (B) shows the incomplete healing of the endothelium, and the 
poorly differentiated endothelial cells (green arrows). (C) shows a poorly covered strut surrounded 
by inflammatory cells and a loose matrix substrate. 300 micron scale bar. 
 
 
 
Of the 72 struts observed microscopically roughly 40% (29 total), showed distinct 
multinucleated giant cell encasement. Out of the others, 17 had direct contact with the 
lumen, meaning they had little to no endothelial covering. Furthermore 40 struts showed 
a mild to severe cellular inflammatory response consisting of lymphocytes, 
macrophages, and scattered neutrophils indicative of the active healing. The health and 
maturity of the endothelium was also evaluated. Roughly 40% of the endothelium 
observed was poorly differentiated and had the appearance of large, puffy mesothelium 
 32 
cells attempting to form a monolayer over the neointima and immature organizing 
thrombus noted on the distal portion of the vessel. The connective tissue substrate 
beneath the unhealed struts was a mixture of immature mixomatous and loose 
connective tissue. 
 
Case 7: Complex Multiple Implantation 
The last chronic case has a long and complicated history. The patient, a 62 year-old 
white male as of 2011, first had a PCI with stenting of the RCA in 2002. Seven years 
later the patient presented with an acute myocardial infarction (MI) and received 6 
stents, a DES in the proximal and distal RCA, and 4 BMS in the middle RCA.  The 
oldest implant was determined to be a Boston Scientific Liberte BMS. The Boston 
scientific Taxus DES shares a strut design with the Liberte DES, but was not FDA 
approved for use in the United States until 2003; therefore this implant must be the BMS 
variety. The BMS in the middle RCA implanted in November 2009 were determined to 
be Medtronic Crown stents. The DES implanted in the proximal and distal regions were 
identified as Boston Scientific Promus stents, approved by the FDA in 2008. The patient 
received a transplant in 2011. X-ray and CT analysis revealed diffuse to confluent 
calcific plaques along the length of the entire RCA (Figure 10B). The vessel was too 
long and articulated to reliably and safely inject contrast media into the lumen without 
risking complications with infiltration and embedding. The distal tip of the vessel needed 
to be cut 1 cm from the end in order to fit the entire vessel in the embedding mold, the 
cut portion was embedded alongside the main artery. 
 
To approach such a long and complicated lesion, the vessel was divided into four 
portions (Figure 10A). In each section landmarks from the CT volume were noted. The 
first area of interest is a nodule of calcium between two sets of stent implants, both 
within the neointima of the older implant, and outside the struts of the newer implant 
(Figure 10F, Cut 4). A section was taken of the oldest of the stents in the middle-distal 
portion of the RCA (Figure 10H, Cut 6). A section was targeted towards the region of 
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the highest strut density, representing the overlap of five different stents at the same spot 
(Figure 10C, Cut 1). Further sections were also taken of each region evenly spaced along 
the length of the vessel. In total, 15 sections were obtained from the RCA.   
 
Subgross evaluation of cut 1 (Figure 10C) shows the area of the RCA with the highest 
density of metal struts, totaling 5 stents in the same area. The oldest DES implant is 
shown pressing against the media of the vessel, which shows signs of degeneration 
(Figure 11A). Adjacent to one of the struts are trapped erythrocytes and fibrin (Figure 
11A, green arrows). Within this DES are small nodules of focal calcification of the 
neointima (Figure 11B). Finally inside of these nodules, slightly depressing them as they 
rest against the neointima of the DES are 4 more BMS implanted in 2009. Although 
these implants are all greater than 2 years old, there is very little neointimal growth 
within the latest round of BMS implants, presumably due to the effects of the DES just 
underneath them. All but 2 struts are covered by endothelium; 2 struts are exposed to the 
lumen; and 2 struts shows fibrin accumulation with enmeshed erythrocytes (Figure 
11A). 
 
Moving distally roughly 1cm to cut 2 (Figure 11D) the DES is no longer present in the 
vessel wall. The calcified plaque is slightly larger and occupies 35% of the vessel wall 
and all 4 BMS implants can be seen. The oldest implant can be seen resting against the 
media, which is thinner here compared to the first section. The stent struts contralateral 
to the plaque were dislodged during handling and transport of the specimen. All but 3 
struts are covered by endothelium. An athermanous plaque between the two oldest and 
two newest implants can be seen occupying roughly 30% of the neointima on that side. 
Within the plaque is a focal nodule of mineralization. 
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Figure 10: Subgross Sectioning Overview. X-ray and MicroCT renderings along with representative 
regions from the entire vessel are shown. 300 micron scale bar. 
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Approximately 1 cm distal to cut 2 is cut 3 (Figure 11E). Here the mineralized plaque 
becomes bilateral and occupies 80% of the media. Two BMS implants can be seen; one 
implanted 2 weeks before the other. The newer of the implants expanded the lumen of 
the older, and restored roughly 60% of flow through the vessel. A pair of over expanded 
struts can be seen pressing against the media on the right side of the slide. Adjacent to 
this area is a rupture of the internal elastic lamina, possibly due to bilateral constraint of 
the expanding balloon by the mineralized plaques, which led to a perpendicular 
overexpansion of the stent struts towards the un-mineralized side. Medial disruption also 
may have been the driving force behind the increased neointima proliferation seen in this 
area. 
 
MicroCT analysis showed an area of pronounced mineralization within the stent struts of 
the older implant and the newer two implants placed two weeks earlier several 
centimeters distal to cut 3. The mineralized neointima plaque occupies roughly 45% of 
the circumference of the neointima and is measured on microCT to be several 
millimeters long. The primary mineralized plaque is larger still, occupying roughly 55% 
of the vessel wall contralateral to the neointima mineralization. The peri-strut substrate is 
a mixture of loose fibrin and mixomatous connective tissue and cells with a mild 
inflammatory infiltrate of neutrophils and macrophages, indicative of chronic irritation 
(Figure 11C). The presence of active inflammation and immature connective tissue is a 
marked change from the dense fibrous appearance of the peristrut regions seen in cuts 1-
3. A clear rupture of the internal elastic lamina can be seen along the edge of the media 
(Figure 11D). Almost all of the outermost implant’s struts can be seen in contact with, or 
infiltrating, the media. This information, combined with the internal elastic lamina 
rupture, possibly explains the marked increase in neo intima proliferation at this level; 
which produced a total in stent restenosis of roughly 60%. 
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Figure 11: Specific Findings. High magnification of specific regions of the vessel show relevant 
findings. 300 micron scale bar. 
 
 
 
The next section, cut 5 (Figure 10G, shows a mineralized plaque that is even larger; 
measuring roughly the same size as the stented vessel and occupying 55% of the vessel 
wall. The only stent in this area is one of the 2-year duration implants. Of note, the struts 
are in contact with the media of the vessel wall but do not penetrate the internal elastic 
lamina. There was no evidence of medial disruption, although the media is quite thin in 
this area similar to cuts 1 and 2. There is minimal neointima proliferation at this level, as 
the vessel lumen remains 95% patent. 
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The final section, Cut 6, represents the oldest of the implants. A bare metal stent 
implanted 9 years prior to transplant. The mineralized plaque is most pronounced at this 
level, dwarfing the size of the stented vessel and occupying 70% of the vessel wall. The 
plaque, prior to stenting, occupied over 95% of the vessel lumen. And when the BMS 
was implanted it expanded contralateral to the plaque and ruptured the internal elastic 
lamina, which cannot be seen on this slide due to degeneration of both the lamina and 
the media. Figure 11F shows the stent strut is resting on collagen in the adventitia, with 
no signs of a medial layer of smooth muscle or an internal or external elastic lamina. The 
neointima occupies 90% of the stented lumen, residual post explant blood can also be 
seen in the lumen.  
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5. DISCUSSION AND CONCLUSION 
 
In the first acute case we located the definitive site where the vulnerable plaque ruptured, 
spilling its thrombogenic contents into the bloodstream. There was no way to tell if the 
rupture occurred before or after the stent was implanted, as rupture of a vulnerable 
plaque is sometimes the cause of acute myocardial infarction which would have led to 
the stenting of the artery. Demonstating the proof of concept of the ability to locate and 
observe the definitive site of a soft plaque rupture at autopsy reinforces the value of 
these techniques. 
Case 2 involved the implantation of a series of stents in a heavily mineralized vessel. We 
believe the expansion force during implantation drove two large calcified lesions apart at 
a branch vessel, leading to a dissection of the wall of the vessel through the media and 
adventitia resulting in hemorrhage and edema of the surrounding tissue. Serial sectioning 
verified the extent of the dissection that traced back to the broken strut that was seen on 
microCT protruding into the wall of the vessel. Were it not for the cross-validation 
capabilities of histology and microCT we could not have been able to say for certain if 
the lesion was real or merely handling artifact. 
Case 3 was originally an example of the deleterious effects of forgoing antiplatelet 
therapy after implantation of a DES. Further evaluation, however, revealed an acute 
vulnerable lipid plaque rupture that produced a thromboembolic nidus that sent emboli 
downstream to produce the small acute and sub-acute myocardial infarctions observed 
clinically. It is unfortunate that iatrogenic handling damage to the vessel obscured the 
definitive site of rupture, but evidence of the rupture such as erythrocytes and acute 
fibrin deposition within the plaque can be seen in serial section downstream from the 
supposed rupture site. Cases like these are a prime example of why clinical testing of 
interventional medical devices is so difficult; because the confounds of diseased arteries 
may obscure clinical outcomes based studies. However a direct pathology examination 
of the vessel revealed what was really going on. 
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Case 4 is another case where a ruptured soft plaque released its contents into the lumen 
of the vessel. An additional mural thrombus, however, adhered to the wall of the vessel 
that was covered with a fibrous cap. The cap can be seen on the proximal and distal most 
sections of the vessel where only the leading and trailing edge of the stent contacted the 
wall. However in the middle of the stent, when the stent expanded the lumen of the 
vessel, the thrombus was pressed through the struts and extruded into the lumen. The 
pieces of the thrombus that were dissected may have remained attached to the wall only 
to get lost during processing. Or rather, they may have also broken free to go 
downstream to contribute to the perioperative myocardial infarction that led to the 
patient’s demise. This case is a good example of an off label use of a stent in the vicinity 
of a vulnerable mural thrombus. Evaluation of vessels like these at autopsy could 
generate information that will be relayed back to cardiologists to guide future off-label 
use of these devices. 
In case 5 the cardiologists were wondering why the vessel was slowly continuing to 
become more stenosed two years after implant. Based on our observations the stent was 
over-expanded within the vessel producing a rupture of the internal elastic lamina 
contralateral to a calcified plaque. It was not necessarily an overabundance of expansion 
pressure at the time of implant. Rather the calcified plaque that occupied a large part of 
the vessel resisted the expansion of one side of the stent struts enough to direct the 
majority force of the expansion towards the opposite side. The presence of the metal 
device in the media of the vessel wall and the rupture of the internal elastic lamina led to 
a smoldering long term immune response that drove the expansion and proliferation of 
smooth muscle cells in the neointima. 
In case 6 the DES, which should have completely eluted its entire drug load in the first 
few months of implant and allowed the healing process to finish was still suppressing the 
healing process around a majority of the stents 6 years after implant. Some of the struts 
showed signs of healing and encapsulation, but over the length of the stent a large 
number were still exposed to the lumen. In one region they were overlapping a branch 
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vessel and remained unendothelialized. Although there was a similar internal elastic 
lamina rupture and medial disruption found in this case when compared to case 5, the 
lumen was significantly more patent. Because the lumen remained patent this device 
would have been considered a success. No one would have known about the state of the 
stent struts in the lumen or the unhealed appearance of the peri-strut regions of this 
vessel had this evaluation not been done at the microscopic level.  
In the last case, case 7, the complexity of the case presents many interesting implications 
for the evaluation of the healing response to these implants. Complex interactions such 
as; multiple BMS implanted in an old DES; the effects of medial disruption in the distal 
end of the vessel, and lack thereof in the proximal end on the healing process; and the 
rate of neointimal growth across multiple regions can be observed within the same 
specimen. The differences between disruption of the media and the subsequent healing 
response can be seen near both bare metal stents and drug eluting stents. Furthermore, 
atherosclerotic change to the neointima(4) over 9 years of implant duration, including 
mineralization and its response to repeat stenting can be seen; a phenomenon that has not 
been published before in the literature with this level of detail. 
When processing the samples for histology, the microCT was invaluable for locating 
areas of interest and for validating the findings from histology. When questions arose 
about the three dimensional configuration of certain observations like the extent of the 
calcification in case 2, microCT data was able to provide the necessary information. 
The quality of the histology sections that we produced is the real driving force behind 
the power of the observations. High resolution cellular detail gave us the ability to 
demonstrate the healing response in the chronic implants, as well as locate and isolate 
acute lesion sites. Using these techniques on a large scale as part of a routine autopsy of 
patients implanted with metal stents could provide a wealth of information for 
cardiologists and biomedical engineers and lead to tangible improvements in patient 
care. 
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